Trial document
DRKS00009815
Trial Description
Title
Attentional processes and decision making in social interactions - Investigation of alterations in individuals with Borderline Personality Disorder and the relationship to different hormones
Trial Acronym
Social_Perception 2
URL of the Trial
[---]*
Brief Summary in Lay Language
People extremely differ in their perception of social situations, in their attentional focus, and in their ability to make decisions within social Encounters. Former research has shown that hormones may strongly influence our behaviour in social situations and our interactions with others. This (EEG-) study investigates the influence of oxytocin on the perception of and the reaction to facial expressions. Oxytocin is a hormone that plays a crucial role in attachment, social relationships, and the recognition of emotions in others.
Brief Summary in Scientific Language
People extremely differ in how fast they react to visual stimuli in competitive situations. Former research has shown that different factors like the ability of our brain to regulate attentional and decision making processes and emotions. It has also been shown that hormones strongly influence our behaviour in social situations and our interactions with others. This (EEG-) study investigates the influence of oxytocin on the perception of and the reaction to facial expressions.
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00009815
- 2016/01/11
- [---]*
- yes
- Approved
- S-032/2015, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
Secondary IDs
- [---]*
Health Condition or Problem studied
- F60.31 - [generalization F60.3: Emotionally unstable personality disorder]
- Healthy Volunteers
Interventions/Observational Groups
-
BPD-Oxytocin condition: 25 female patients with BPD, one intranasal Administration of 24 I.U. oxytocin; after clinical diagnostic interviews (International Personality Disorder Examination; Loranger et al. 1994 and SCID-I) as well as several dimensional questionnaires for the assessment of clinical symptoms and personality traits (Borderline-Symptom-Liste; Bohus et al., 2007; Zanarini Scale; Zanarini et al. 2003; German Version of the Difficulty in Emotion Regulation Scale; Gratz et al., 2004; German version of the Childhood Trauma Questionnaire; Bernstein et al., 1998; German version of the State-Trait Anger Inventory; Spielberger, 1991; German Version of the State-Trait Anxiety Inventory; Laux et al., 1981; German version of the Barrat Impulsivity Scale; Patton et al., 1995; Dissociation; Freyberger, 1999; Multidimensional Mood Questionnaire; Steyer et al. 1997; Rejection Sensitivity; Bungert et al., in press; Screening Questionnaire for Hormone Assessments; Schultheiss & Stanton,
2009; Life History of Aggression Inventory; Coccaro et al. 1997; Overt Aggression Sale Modified for Outpatients; OAS-M, Coccaro et al., 1991; Raven Matrices; Heller, 1981) one blood sample will be drawn for hormonal assessments. Participants will then be intranasally administered with 24 I.U. oxytocin or a placebo spray. In the following two Tasks, participants rate different facial expressions of a set of facial cues while an EEG is recorded. - BPD-Placebo condition: 25 female patients with BPD, one intranasal Placebo Administration intranasal; see Arm 1 for procedure
- HC-Oxytocin condition: 25 female healthy volunteers; one intranasal Administration of 24 I.U. oxytocin; see Arm 1 for procedure
- HC-Placebo condition: 25 female healthy volunteers, one intranasal Placebo Administration intranasal; see Arm 1 for procedure
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Blinded
- patient/subject, investigator/therapist
- Other
- Basic research/physiological study
- Other
- N/A
- No
Primary Outcome
Behavioral Data: Performance and reaction time; EEG: P1, N170, P300 for emotional faces after a single oxytocin vs. placebo administration in female BPD patients vs. healthy controls
Secondary Outcome
Exploratory correlations between behavioral and EEG data (see Primary outcome) and dimensional trait questionnaires (anger, German version of the State-Trait Anger Inventory; Spielberger, 1991; anxiety, German Version of the State-Trait Anxiety Inventory; depression, Beck Depression Inventory; aggressiveness, Life History of Aggression Inventory; Coccaro et al. 1997; Overt Aggression Sale Modified for Outpatients; OAS-M, Coccaro et al., 1991) after single oxytocin vs. Placebo Administration in female BPD patients vs. healthy volunteers.
Countries of Recruitment
- Germany
Locations of Recruitment
- University Medical Center
Recruitment
- Actual
- 2016/01/01
- 100
- Monocenter trial
- National
Inclusion Criteria
- Female
- 18 Years
- 50 Years
Additional Inclusion Criteria
General inclusion criteria: age 18-50 years, readiness for participation. Additional inclusion criterion for patients with Borderline Personality Disorder: Borderline Personality Disorder assessed with the International Personality Disorder Examination.
Exclusion Criteria
General exclusion criteria: actual pregnancy, lifetime diagnosis of any psychotic or bipolar disorders, substance dependence during the past year, a history of brain damage, severe internistic or neurological disease, claustrophobia. Additional exclusion criterion for healthy controls: more than one DSM-IV criterion for Borderline Personality Disorder fulfilled.
Addresses
-
start of 1:1-Block address primary-sponsor
- Klinik für Allgemeine Psychiatrie Universitätsklinikum Heidelberg
- Ms. Dr. Katja Bertsch
- Voßstraße 4
- 69115 Heidelberg
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- 06221 5636502
- [---]*
- katja.bertsch at med.uni-heidelberg.de
- http://www.klinikum.uni-heidelberg.de/Klinik-fuer-Allgemeine-Psychiatrie.1798.0.html
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- Klinik für Allgemeine Psychiatrie Universitätsklinikum Heidelberg
- Ms. Dr. Sabrina Boll
- Voßstraße 4
- 69115 Heidelberg
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 06221 5634861
- [---]*
- sabrina.boll at med.uni-heidelberg.de
- http://www.klinikum.uni-heidelberg.de/Klinik-fuer-Allgemeine-Psychiatrie.1798.0.html
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Klinik für Allgemeine Psychiatrie Universitätsklinikum Heidelberg
- Ms. Dr. Sabrina Boll
- Voßstraße 4
- 69115 Heidelberg
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 06221 5634861
- [---]*
- sabrina.boll at med.uni-heidelberg.de
- http://www.klinikum.uni-heidelberg.de/Klinik-fuer-Allgemeine-Psychiatrie.1798.0.html
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Deutsche Forschungsgemeinschaft
- Kennedyallee 40
- 53175 Bonn
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- http://www.dfg.de
end of 1:1-Block address contact materialSupport
Status
- Recruiting complete, follow-up complete
- 2018/12/31
Trial Publications, Results and other Documents
- [---]*